Syngene International Limited, commonly referred to as Syngene, is a leading global contract research and manufacturing organisation headquartered in Bengaluru, India. Founded in 1993, Syngene has established itself as a key player in the biopharmaceutical industry, providing integrated research and development services to clients across the globe.
With a strong presence in North America, Europe, and Asia, Syngene offers a diverse range of services, including drug discovery, development, and manufacturing. The company is renowned for its innovative approach, leveraging cutting-edge technologies to deliver high-quality solutions tailored to client needs.
Syngene's commitment to excellence has earned it a prominent market position, with notable achievements in collaborations with major pharmaceutical companies. Its unique blend of scientific expertise and operational efficiency sets Syngene apart in the competitive landscape of life sciences.
+40 vs industry average
Syngene’s score of 62 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Syngene?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Health Services has typical carbon intensity
Industry performance
The Health Services industry has increased its overall emissions by 7% since 2019
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Syngene's reported carbon emissions
In 2025, Syngene International Limited reported total greenhouse gas emissions of approximately 66,370,000 kg CO2e from Scope 1, 6,958,000 kg CO2e from Scope 2, and 57,505,000 kg CO2e from Scope 3, leading to a combined total of approximately 135,950,000 kg CO2e. This data reflects a commitment to transparency in emissions reporting, with a focus on all three scopes of emissions. Syngene has set ambitious reduction targets, aiming for a 30% reduction in Scope 1 emissions and a 25% reduction in Scope 2 emissions by 2030, both from a 2021 baseline. Additionally, the company has committed to a significant long-term goal of reducing absolute Scope 1 and 2 GHG emissions by 54.6% by FY2033, using FY2023 as the base year. Furthermore, Syngene aims for 81.6% of its suppliers to have science-based targets by FY2028, enhancing its supply chain sustainability. The company is actively engaged in climate initiatives, having committed to the Science Based Targets initiative (SBTi) and aligning its targets with the 1.5°C pathway. This commitment underscores Syngene's dedication to addressing climate change and reducing its carbon footprint in the pharmaceutical and biotechnology sector.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Syngene’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Syngene yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Syngene
Frequently asked questions
Common questions about Syngene’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project